Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Actinic Keratosis
Interventions: KX2-391 Ointment 1%, Placebo; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more

Conditions: Healthy Volunteers
Interventions: CHK336, Placebo; Drug
Lead sponsor: Chinook Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: OCD
Interventions: CBM-TAF, CBM-SMP; Behavioral
Lead sponsor: Han Joo Lee; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Opioid Use Disorder
Interventions: Placebo, MCAM; Other · Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infertility
Interventions: CCRI Group, Control; Behavioral
Lead sponsor: Boston IVF; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Stroke, Depression, Depressive Symptoms, Post-stroke Depression
Interventions: Dyadic (couples-based) positive psychology intervention; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more

Conditions: Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions: Transdiagnostic Behavior Therapy, Behavioral Activation Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Gout
Interventions: RDEA594, Placebo, Allopurinol; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Transition Empowerment Program, Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC), Online Transition Empowement Program Access; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years to 25 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Caregivers of Alzheimer's Disease or Memory Problem Patients, Caregiver Wellbeing, Elder Abuse
Interventions: Risk Assessment Screening, Coach and Website Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions: Cold and Compression, SOC (Standard of care); Device · Other
Lead sponsor: Ochsner Health System; Other
Eligibility: 50 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Overweight, Healthy Subjects
Interventions: SAR441255, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Glabellar Frown Lines (GL)
Interventions: EB-001 injection, Placebo injection; Drug
Lead sponsor: Bonti, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Fremont, California • Newport Beach, California

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more

Conditions: Degenerative Disc Disease
Interventions: Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture, Placebo; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 47
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 42 more

Conditions: Obesity, Obese
Interventions: HM17321, Placebo of HM17321; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Phonotrauma
Interventions: Acoustic voice analysis, High-speed videoendoscopy; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions: FX006, Normal Saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Pre Diabetes, Overweight and Obesity
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type2 Diabetes, Overweight and Obesity
Interventions: WW program modified for people with Type 2 diabetes; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Gainesville, Florida • Baton Rouge, Louisiana • Richmond, Virginia

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Epilepsy, Insomnia
Interventions: GoToSleep Program; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

Effect of Psychological Intervention on Drop-out Rates in IVF

Testing a Positive Psychology-based Intervention for Couples Coping With Stroke

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

Allopurinol Combination Study

Let's Empower and Prepare Young Adults With Type 1 Diabetes

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Risk Screening & Primary Prevention of Elder Abuse in People Living With Dementia

Cold and Compression Post TKA

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Patients With and Without Phonotrauma

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

TRE With Physical Activity for Weight Management

Virtual Weight Control Program Tailored for Adults With Type 2 Diabetes (VITAL)

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

A Computerized CBTi for Insomnia in Epilepsy